MDACC Study No:2010-0453 ( NCT No: NCT01196208)
Title:An open-label, treatment-option protocol of brentuximab vedotin in
patients with relapsed or refractory Hodgkin lymphoma or relapsed
or refractory systemic anaplastic large cell lymphoma
Principal Investigator:Michelle A. Fanale
Treatment Agent:SGN-35
Study Status:Closed
Study Description:The goal of this clinical research study is learn more about the safety of
SGN-35 (brentuximab vedotin) in patients who participated in 2009-0851, were on
placebo, and whose HL has gotten worse. Another goal of this study is to allow
other patients with HL and ALCL whose disease has come back or is not getting
better on another treatment, access to brentuximab vedotin.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II/Phase III
Treatment Agents:SGN-35
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Seattle Genetics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
For Clinical Trial Enrollment:713-792-2806
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults